Claritev (CTEV) SVP Tiffani Misencik Sells $138K of Stock

Inside Tiffani Misencik's Claritev Trade

Claritev Corp (NYSE:CTEV) recently saw insider activity as Tiffani Misencik, the company's SVP and Chief Growth Officer, sold 5,812 shares. According to a Form 4 filed with the SEC, the shares went at an average price of $23.81, for a total transaction value of $138,390.11. This planned trade, executed on October 15, 2026, reduced her direct holdings in the healthcare information services firm.

Other Institutional Activity in Claritev

Large outside funds hold major stakes in the company, with several keeping their positions steady in recent quarters. H&F Corporate Investors VIII, Ltd. held 3,887,858 shares valued at $85,999,422. Ares Management LLC maintained its holding of 1,863,105 shares worth $41,211,884. Arini Capital Management Ltd reported 1,534,687 shares valued at $33,947,277, while Public Investment Fund held 1,281,250 shares worth $28,341,251. Meanwhile, Beach Point Capital Management LP trimmed its position by 24,735 shares, ending the period with 706,120 shares worth about $17,045,938.

Claritev Corp Stock Down 7.8%

Shares of Claritev recently traded around $21.99 as of October 16, 2026. That puts the stock below its 50-day moving average of $31.70 and under its 200-day moving average of $26.25. The price sits well below the 52-week high of $73.68, though it remains above the 52-week low of $11.50.

Recent Earnings

For the trailing twelve months, Claritev posted revenue of $994,668,992 alongside a net margin of -28.5%. The company reported a trailing EPS of -17.0, and year-over-year revenue growth reached 6.6%. The firm's next earnings update is scheduled for November 9, 2026.

Insider Buying and Selling at Claritev Corp

Insiders have been active throughout the past few months. On August 10, 2026, officer William B Mintz sold 8,431 shares at $34.24 apiece for a total of $288,677. A few days later on August 14, 2026, officer Tiffani Misencik sold 8,850 shares at $40.07 each, totaling $354,593. Later, on August 28, 2026, CEO Travis Dalton bought 6,450 shares worth $249,664. CFO Douglas Michael Garis then sold 9,025 shares on September 21, 2026, for a total of $276,075.

Analysts Set New Price Targets

Financial firms regularly update their views on the stock. On July 21, 2026, Canaccord Genuity kept a Buy rating and raised its target to $37.00. Citigroup followed on August 10, 2026, maintaining a Buy rating while lifting its target to $45.00. Canaccord Genuity updated its target again on August 10, 2026, moving it to $43.00 with a Buy rating. Wells Fargo kept an Equal-Weight rating on August 12, 2026, raising its target to $30.00, and Barclays maintained an Overweight rating on August 21, 2026, while bumping its target to $40.00. Across five analyst opinions, the mean target price sits at $46.00.

About Claritev

Claritev Corporation operates out of McLean, Virginia, providing cost management, payment, and revenue integrity solutions to the U.S. healthcare sector. The firm uses data analytics and technology platforms to help organizations handle complex medical billing and administrative workflows. Insider transactions like this give everyday investors a window into how company leaders manage their personal stock portfolios.

Bottom Line

Investors will likely keep a close eye on Claritev ahead of its upcoming earnings release on November 9, 2026. Future regulatory filings will show whether other executives or major shareholders adjust their positions following this recent insider sale.